A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) (NCT06431594)
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (65 Sites)
Showing the first 25 of 65 sites.
- GSK Investigational Site — Birmingham, Alabama
- GSK Investigational Site — Fountain Valley, California
- GSK Investigational Site — Santa Rosa, California
- GSK Investigational Site — Lake Mary, Florida
- GSK Investigational Site — Orlando, Florida
- GSK Investigational Site — Fairway, Kansas
- GSK Investigational Site — Boston, Massachusetts
- GSK Investigational Site — Boston, Massachusetts
- GSK Investigational Site — Detroit, Michigan
- GSK Investigational Site — Grand Rapids, Michigan
- GSK Investigational Site — Minneapolis, Minnesota
- GSK Investigational Site — Mineola, New York
- GSK Investigational Site — New York, New York
- GSK Investigational Site — Portland, Oregon
- GSK Investigational Site — Nashville, Tennessee
- GSK Investigational Site — Dallas, Texas
- GSK Investigational Site — West Valley City, Utah
- GSK Investigational Site — Seattle, Washington
- GSK Investigational Site — Cipoletti Rio Negro,
- GSK Investigational Site — Ciudad de Buenos Aires,
- GSK Investigational Site — La Plata,
- GSK Investigational Site — Rosario,
- GSK Investigational Site — Blacktown, New South Wales
- GSK Investigational Site — Macquarie University, New South Wales
- GSK Investigational Site — Leuven,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.